CoviStat

CoviStat is a clinical-stage biotechnology company and a subsidiary of Atossa Therapeutics focused on developing therapeutic interventions for respiratory infections, specifically COVID-19. The company's primary program, AT-H201, is a proprietary inhaled therapeutic designed to treat patients by potentially blocking the SARS-CoV-2 virus from entering host cells and improving lung function. CoviStat was established to accelerate the development of antiviral treatments using combination drug strategies and specialized delivery mechanisms. While operating as a subsidiary, the company leverages the research and clinical infrastructure of its parent organization, Atossa Therapeutics, to advance its pipeline through clinical trials.